This clinical trial is focused on studying the effectiveness and safety of different types of vaccines for influenza, commonly known as the flu, in adults aged 50 years and older. The study involves a high-dose vaccine called aQIVc HD, which is a cell-derived vaccine enhanced with an ingredient called MF59 to boost the immune response. It is compared with two other vaccines: a non-enhanced vaccine called QIVr and another enhanced vaccine called aQIV, which is derived from eggs.
The purpose of the study is to evaluate how well these vaccines work in producing an immune response and how safe they are for the participants. The study will involve receiving one of the vaccines through an injection. Participants will be monitored for their immune response to the vaccine strains, which are specific types of the flu virus, and for any side effects. The study will last for about a year, with the main focus on the immune response measured at 29 days after vaccination.
Participants will include healthy individuals or those with stable health conditions that increase their risk of complications from the flu. The study aims to ensure that the high-dose vaccine is as effective and safe as the other vaccines. The vaccines are administered using a pre-filled syringe, which is a single-use device. The study will help determine the best vaccine option for older adults to protect them against the flu.



Denmark
Estonia
Germany